Research in Motion ( RIMM) estimates cut at JP Morgan through 2014, JP Morgan said. Weaker outlook for Blackberry 7 sales. Sarepta ( SRPT) estimates, target boosted at JMP. Shares of SRPT now seen reaching $50, according to JMP Securities. Estimates also upped, given the clinical efficacy of its muscular dystrophy drug. Outperform rating. >To submit a news tip, email: firstname.lastname@example.org.